Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer

Prostate cancer is a common cancer, and a significant cause of cancer death in men. There are many potentially curative treatment options for prostate cancers that have not spread. A relatively recent option is called prostate stereotactic ablative radiotherapy (SABR). SABR is a form of external beam radiotherapy, where patients receive a small number (5-7) of treatments (also called fractions) of radiation delivered in a highly accurate and precise fashion. Standard prostate SABR is generally given in 5 fractions and has been shown to be at least as effective as conventional external beam rad

Trial Details

NCT ID

NCT06835725

Phase

PHASE2

Sponsor

British Columbia Cancer Agency

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• Stereotactic Body Radiation Therapy (SBRT)

Locations (sample)

• Surrey, British Columbia, Canada|49.10635,-122.82509
• Victoria, British Columbia, Canada|48.4359,-123.35155

Key Eligibility Criteria

• • Age 18 or older.
• Able to provide informed consent.
• ECOG performance status 0 - 2.
• Fit for all protocol treatment and follow-up.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →